首页> 外文期刊>The Lancet >Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis.
【24h】

Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis.

机译:抗结核药物耐药性流行病学(全球抗结核药物耐药性监测项目):最新分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The burden of tuberculosis is compounded by drug-resistant forms of the disease. This study aimed to analyse data on antituberculosis drug resistance gathered by the WHO and International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. METHODS: Data on drug susceptibility testing for four antituberculosis drugs--isoniazid, rifampicin, ethambutol, and streptomycin--were gathered in the third round of the Global Project (1999-2002) from surveys or ongoing surveillance in 79 countries or geographical settings. These data were combined with those from the first two rounds of the project and analyses were done. Countries that participated followed a standardised set of guidelines to ensure comparability both between and within countries. FINDINGS: The median prevalence of resistance to any of the four antituberculosis drugs in new cases of tuberculosis identified in 76 countries or geographical settings was 10.2% (range 0.0-57.1). Themedian prevalence of multidrug resistance in new cases was 1.0% (range 0.0-14.2). Kazakhstan, Tomsk Oblast (Russia), Karakalpakstan (Uzbekistan), Estonia, Israel, the Chinese provinces Liaoning and Henan, Lithuania, and Latvia reported prevalence of multidrug resistance above 6.5%. Trend analysis showed a significant increase in the prevalence of multidrug resistance in new cases in Tomsk Oblast (p<0.0001). Hong Kong (p=0.01) and the USA (p=0.0002) reported significant decreasing trends in multidrug resistance in new cases of tuberculosis. INTERPRETATION: Multidrug resistance represents a serious challenge for tuberculosis control in countries of the former Soviet Union and in some provinces of China. Gaps in coverage of the Global Project are substantial, and baseline information is urgently required from several countries with high tuberculosis burden to develop appropriate control interventions.
机译:背景:结核病的负担与该病的耐药性形式有关。这项研究旨在分析由世界卫生组织和国际抗结核和肺病联盟抗结核药物耐药性监测全球项目收集的抗结核药物耐药性数据。方法:在全球项目的第三轮(1999-2002年)中,通过对79个国家或地区的调查或正在进行的监测,收集了四种抗结核药物(异烟肼,利福平,乙胺丁醇和链霉素)的药敏试验数据。这些数据与项目前两轮的数据相结合,并进行了分析。参加的国家遵循一套标准化的准则,以确保国家之间和国家内部的可比性。结果发现,在76个国家或地区确定的结核病新病例中,对四种抗结核药物中任何一种的耐药性的中位患病率为10.2%(范围0.0-57.1)。在新病例中,多药耐药性的提神病患病率为1.0%(范围0.0-14.2)。哈萨克斯坦,托木斯克州(俄罗斯),卡拉卡尔帕克斯坦(乌兹别克斯坦),爱沙尼亚,以色列,中国辽宁省和河南省,立陶宛和拉脱维亚等省报告多药耐药率高于6.5%。趋势分析显示,在托木斯克州的新病例中,多重耐药性的患病率显着增加(p <0.0001)。香港(p = 0.01)和美国(p = 0.0002)报告了在新的结核病例中多药耐药性的显着下降趋势。解释:在前苏联国家和中国某些省份,对结核病的多重控制对结核病的控制构成了严峻挑战。全球项目的覆盖范围很大,迫切需要几个结核病负担高的国家提供基准信息,以制定适当的控制干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号